| Income Statement | 2026-04-30 | |||
|---|---|---|---|---|
| Research, development, and clinical trial expenses, net | 5,966,673 | |||
| General and administrative expenses | 1,654,121 | |||
| Total operating expenses | 7,620,794 | |||
| Operating loss | -7,620,794 | |||
| Financial (income) expenses, net | 186,970 | |||
| Change in fair value of the warrant liability | -123,242 | |||
| Unrealized gain on investment | 137,830 | |||
| Share of loss on equity investment | -64,303 | |||
| Net loss for the period | -7,237,055 | |||
| Net loss attributable to non-controlling interest | -72,548 | |||
| Net loss and comprehensive loss for the period attributable to briacell | -7,164,507 | |||
| Basic EPS | -0.99 | |||
| Diluted EPS | -0.99 | |||
| Basic Average Shares | 7,250,487 | |||
| Diluted Average Shares | 7,250,487 | |||
BriaCell Therapeutics Corp. (BCTXL)
BriaCell Therapeutics Corp. (BCTXL)